tert-Butyl 4-(1-hydroxypropan-2-yl)piperazine-1-carboxylate

Catalog No. :
ACGOUV084
CAS No. :
900535-75-3
Molecular Formula :
C12H24N2O3
Molecular Weight :
244.34

IUPAC Name:tert-butyl 4-(1-hydroxypropan-2-yl)piperazine-1-carboxylate

tert-Butyl 4-(1-hydroxypropan-2-yl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg98%$434.00Login to see priceIn stockInquiry
250mg98%$612.00Login to see priceIn stockInquiry
1g98%$1218.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(1-hydroxypropan-2-yl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(1-hydroxypropan-2-yl)piperazine-1-carboxylate
MDL No.MFCD17480392
Molecular FormulaC12H24N2O3
Molecular Weight244.34
SMILESO=C(N1CCN(C(C)CO)CC1)OC(C)(C)C
InChI KeyOLQYUDUDNCDQPU-UHFFFAOYSA-N
Synonym4-(2-Hydroxy-1-methyl-ethyl)-piperazine-1-carboxylic acid tert-butyl ester;tert-butyl 4-(1-hydroxypropan-2-yl)piperazine-1-carboxylate;1-Piperazinecarboxylic acid, 4-(2-hydroxy-1-methylethyl)-, 1,1-dimethylethyl ester
CAS No.900535-75-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H315-H319
Precautionary Statement(s)
P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364

Synthetic Route by SureRoute

1. ACGOUV084 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEAWL439 route compound structure diagram
    ACEAWL439680579-19-5 In Stock
  2. Then
  3. ACGOUV084 route product structure diagram
    ACGOUV084900535-75-3 In Stock
Inquiry

2. ACGOUV084 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACEAWL439 route compound structure diagram
    ACEAWL439680579-19-5 In Stock
  4. Then
  5. ACGOUV084 route product structure diagram
    ACGOUV084900535-75-3 In Stock
Inquiry

Comments (0)